Résumé
Déf.: Groupe hétérogène de tumeurs malignes de la bouche, du nez et de la partie supérieure du système respiratoire.
Preview
Unable to display preview. Download preview PDF.
Réf.
Bernier J, Domenge C, Ozsahin M et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004;350:1945–1952
Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for squamous cell carcinoma of the head and neck. N Engl J Med 2006;354:567–578
Colevas AD. Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2006;24:2644–2652
Cooper JS, Pajak TF, Forastiere AA et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous cell carcinoma of the head and neck. N Engl J Med 2004;350:1937–1944
ESMO Guidelines Working Group. Squamous cell carcinoma of the head and neck: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2007;18(Suppl 2):ii65–66
Le Tourneau C, Faivre A, Siu LL. Molecular targeted therapy of head and neck cancer: Review and clinical development challenges. Eur J Cancer 2007;43:2457–2466
Posner MR, Hershock DM, Blajman CR et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007;357:1705–1715
Salama JK, Seiwert TY, Vokes EE. Chemoradiotherapy for locally advanced head and neck cancer. J Clin Oncol 2007;25:4118–4126
Seiwert TY, Cohen EEW. State-of-the-art management of locally advanced head and neck cancer. Br J Cancer 2005;92:1341–1348
Réf.
Blackstock AW, Govindan R. Definitive chemoradiation for the treatment of locally advanced NSCLC. J Clin Oncol 2007;25:4146–4152
ESMO Guidelines Working Group. NSCLC: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2007;18(suppl 2):ii30–31
ESMO Guidelines Working Group. SCLC: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2007;18(Suppl.2):ii32–33
Jackman DM, Johnson BE. Small-cell lung cancer. Lancet 2005;366:1385–1396
Lally BE, Urbanic JJ, Blackstock AW et al. SCLC: have we made any progress over the last 25 years? Oncologist 2007;12:1096–1104
Pfister DG, Johnson DH, Azzoli CG et al. ASCO treatment of unresectable non-small-cell lung cancer guideline: Update 2003. J Clin Oncol 2004;22:330–353
Pfister KMW, Evans WK, Azzoli CG et al. Cancer Care Ontario and ASCO adjuvant chemotherapy and adjuvant radiation therapy for stages I–IIIA resectable NSCLC Guideline. J Clin Oncol 2007;25:5506–5518
Ramalingam S, Belani C. Systemic chemotherapy for advanced NSCLC: recent advances and future directions. Oncologist 2008;13:5–13
Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for NSCLC. N Engl J Med 2006;355:2542–2550
Réf.
Bofetta P. Epidemiology of peritoneal mesothelioma: a review. Ann Oncol 2007; 18:985–990
Ceresoli GL, Betta GP, Castagneto B et al. Malignant pleural mesothelioma. Ann Oncol 2006;17(suppl 2):ii13–16
ESMO Guidelines Working Group. Malignant pleural mesothelioma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2007;18(Suppl. 2):ii34–35
Hassan R, Alexander R, Antman K et al. Current treatment options and biology of peritoneal mesothelioma. Ann Oncol 2006;17:1615–1619
Robinson BWS, Lake RA. Advances in malignant mesothelioma. N Engl J Med 2005;353:1591–1603
Vogelzang NJ, Rusthoven JJ, Symanowski J et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636–2644
Zucali PA, Giaccone G. Biology and management of malignant pleural mesothelioma. Eur J Cancer 2006;42:2706–2714
Réf.
De Jong WK, Blaauwgeers JLG, Schaapveld M et al. Thymic epithelial tumors: A population-based study of the incidence, diagnostic procedures and therapy. Eur J Cancer 2008;44:123–130
Giaccone G. Treatment of malignant thymoma. Curr Opin Oncol 2005;17:140–146
Riedel RF, Burfeind WR. Thymoma: benign appearance, malignant potential. Oncologist 2006;11:887–894
Réf.
Cunningham D, Starling N, Rao S et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008;358:36–46
ESMO Guidelines Working Group. Esophageal cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2007;18(Suppl. 2):ii15–16
Heitmiller RF. Epidemiology, diagnosis, and staging of esophageal cancer. Cancer Treat Res 2001;105:375–386
Kleinberg L, Forastiere AA. Chemoradiation in the management of esophageal cancer. J Clin Oncol 2007;25:4110–4117
Koshy M, Esiashvilli N, Landry JC et al. Multiple management modalities in esophageal cancer: epidemiology, presentation and progression, work-up, and surgical approaches. Oncologist 2004;9:137–146
MRC Oesophageal Cancer Working Party. Surgical resection with or without chemotherapy in oesophageal cancer. Lancet 2002;359:1727–1733
Souza RF, Spechler SJ. Concepts in the prevention of adenocarcinoma of the distal esophagus and proximal stomach. CA Cancer J Clin 2005;55:334–351
Tew WP, Kelsen DP, Ilson DH. Targeted therapies for esophageal cancer. Oncologist 2005;10:590–601
Van Meerten E, Van der Gaast A. Systemic treatment for oesophageal cancer. Eur J Cancer 2005;41:664–672
Réf.
Ajani JA. Evolving chemotherapy for gastric cancer. Oncologist 2005;10(Suppl. 3):49–58
Cunningham D, Allum WH, Stenning SP et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11–20
De Vita F, Giuliani F, Galzia G. et al. Neo-adjuvant and adjuvant chemotherapy of gastric cancer. Ann Oncol 2007;18(Suppl. 6):vi120–123
ESMO Guidelines Working Party. Gastric cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2007;18(Suppl. 2):ii17–18
Hejna M, Wöhrer S, Schmidinger M et al. Postoperative chemotherapy for gastric cancer. Oncologist 2006;11:136–145
Jansen EPM, Boot H, Verheij M et al. Optimal locoregional treatment in gastric cancer. J Clin Oncol 2005;20:4509–4517
Lim L, Michael M, Mann GB et al. Adjuvant therapy in gastric cancer. J Clin Oncol 2005;23:6220–6332
Matysiak-Budnik T, Mégraud F. Helicobacter pylori infection and gastric cancer. Eur J Cancer 2006;42:708–716
Tabernero J, Macarulla T, Ramos FJ et al. Novel targeted therapies in the treatment of gastric and esophagus cancer. Ann Oncol 2005;16:1740–1748
Réf.
Barnes G, Romero L, Hess KR et al. Primary adenocarcinoma of the duodenum: management and survival in 67 patients. Ann Surg Oncol 1994;1:73–77
Delaunoit T, Neczyporenko F, Limburg PJ et al. Pathogenesis and risk factors of small bowel adenocarcinoma: a colorectal cancer sibling? Am J Gastroenterol 2005;100:703–710
North JH, Pack MS. Malignant tumors of the small intestine: a review of 144 cases. Am J Surg 2000;66:46–51
Stang A, Stegmaier C, Eisinger B et al. Descriptive epidemiology of small intestinal malignancies: the German Cancer Registry experience. Br J Cancer 1999;80:1440–1444
Wheeler JMD, Warren BF, Mortensen NJ et al. An insight into the genetic pathway of the small intestine. Gut 2002;50:218–223
Réf.
Benson AB, Schrag D, Somerfield MR et al. ASCO recommendations on adjuvant chemotherapy or stage II colon cancer. J Clin Oncol 2004;22:3408–3419
Board RE, Valle J. Metastatic colorectal cancer. Drugs 2007;67:1851–1867
Desch CE, Benson AB, Somerfield MR et al. Colorectal cancer surveillance: 2005 update of an ASCO Practice Guideline. J Clin Oncol 2005;23:8512–8519
ESMO Guidelines Working Group. Colon cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2007;18(suppl 2):ii21–22
ESMO Guidelines Working Group. Rectal cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2007;18(suppl 2):ii23–24
ESMO Guidelines Working Group. Advanced colorectal cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2007;18(suppl 2):ii25–26
Jackson C, Cunningham D. Where to position monoclonal antibodies in first-line treatment of advanced colorectal cancer. Eur J Cancer 2008;44:652–662
Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med 2005;352:476–487
Wolpin BM, Meyerhardt JA, Mamon HJ et al. Adjuvant treatment of colorectal cancer. CA Cancer J Clin 2007;57:168–185
Réf.
Clark MA, Hartley A, Geh JI. Cancer of the anal canal. Lancet Oncol 2004;5:149–157
Einstein MH, Kadish AS. Anogenital neoplasia in AIDS. Curr Opin Oncol 2004;16:455–462
Rousseau DL, Thomas CR, Petrelli NJ et al. Squamous cell carcinoma of the anal canal. Surg Oncol 2005;14:121–132
Steinbrook R. The potential of human papillomavirus vaccines. N Engl J Med 2006;354:1109–1112
Uronis HE, Bendell JC. Anal Cancer. Oncologist 2007;12:524–534
Réf.
Cardenes Hr, Chiorean EG, De Witt J et al. Locally advanced pancreatic cancer. Oncologist 2006;11:612–623
Chua YJ, Cunningham D. Adjuvant treatment for resectable pancreatic cancer. J Clin Oncol 2005;23:4532–4537
ESMO Guidelines Working Group. Pancreatic cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2007;18(Suppl. 2):ii19–20
Neoptolemos JP, Stocken DD, Friess H et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004;350:1200–1210
Sultana A, Tudur Smith C, Cunningham D et al. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol 2007;25:2607–2615
Verslype C, Van Cutsem E, Dicato M et al. The management of pancreatic cancer. Ann Oncol 2007;18(Suppl. 7):vii1–vii10
Willett CG, Czito BG, Bendell JC et al. Locally advanced pancreatic cancer. J Clin Oncol 2005;23:4538–4544
Yang GY, Wagner TD, Fuss M et al. Multimodality approaches for pancreatic cancer. CA Cancer J Clin 2005;55:352–367
Réf.
Blum HE. Hepatocellular carcinoma: therapy and prevention. World J Gastroenterol 2005;11:7391–7400
Greten TF, Papendorf F, Bleck JS et al. Survival rate in patients with hepatocellular carcinoma. Br J Cancer 2005;92:1862–1868
Hertl M, Cosimi AB. Liver transplantation for malignancy. Oncologist 2004; 10:269–281
Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907–1917
Mann CD, Neal CP, Garcea G et al. Prognostic molecular markers in hepatocellular carcinoma. Eur J Cancer 2007;43:979–992
Nowak AK, Chow PKH, Findlay M. Systemic therapy for advanced hepatocellular carcinoma. Eur J Cancer 2004;40:1474–1484
Zhu AX. Systematic therapy of advanced hepatocellular carcinoma: how hopeful should we be? Oncologist 2006;11:790–800
Réf.
Anderson CD, Pinson CW, Berlin J et al. Diagnosis and treatment of cholangiocarcinoma. Oncologist 2004;9:43–57
Brugge WR. Endoscopic techniques to diagnose and manage biliary tumors. J Clin Oncol 2005;23:4561–4565
De Groen PC, Gores GJ, LaRusso NF et al. Biliary tract cancers. N Engl J Med 1999;341:1368–1378
Khan SA, Thomas HC, Davidson BR et al. Cholangiocarcinoma. Lancet 2005;366:1303–1314
Patel T. Cholangiocarcinoma. Nat Clin Pract Gastroenterol Hepatol 2006;3:33–42
Randi G, Franceschi S, La Vecchia C. Gallbladder cancer worldwide: geographic distribution and risk factors. Int J Cancer 2006;118:1591–1602
Wistuba II, Gazdar AF. Gallbladder cancer: lessons from a rare tumor. Nature Rev Cancer 2004;4:695–706
Réf.
Beslija S, Bonneterre J, Burstein H et al. Second consensus on medical treatment of metastatic breast cancer. Ann Oncol 2007;18:215–225
Cinierie S, Orlando L, Fedele P et al. Adjuvant strategies in breast cancer: new prospectives, questions and reflections at the end of 2007 St Gallen International Expert Consensus Conference. Ann Oncol 2007;18(Suppl. 6):vi63-5
ESMO Guidelines Working Group. Primary breast cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2007;18(Suppl. 2):ii5–8
ESMO Guidelines Working Group. Recurrent or metastatic breast cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2007;18(Suppl. 2):ii9–11
GoldhirschA, Wood WC, Gelber RD et al. Progress and promise: highlights of the international expert consensus on the pimary therapy of early breast cancer 2007. Ann Oncol 2007; 18:1133–1144
Kaufmann M, von Minckwitz G, Bear HD et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol 2007;18:1927–1934
Khatcheressian JL, Wolff AC, Smith TJ et al. ASCO 2006 update of the breast follow-up and management guidelines in the adjuvant setting. J Clin Oncol 2007;24:5091–5097
Perry N, Broeders M, De Wolf C et al. European guidelines for quality assurance in breast cancer screening and diagnosis. Ann Oncol 2008;19:614–622
Von Minckwitz G. Evidence-based treatment of metastatic breast cancer — 2006 recommendations by the AGO Breast Commission. Eur J Cancer 2006;42:2897–2908
Réf.
Cadron I, Leunen K, Van Gorp T et al. Management of borderline ovarian neoplasms. J Clin Oncol 2007;25:2928–2937
Cannistra SA. Cancer of the ovary. N Engl J Med 2004;351:2519–2529
Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and oral contraceptives. Lancet 2008;317:303–314
DuBois A, Quinn M, Thigpen T et al. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference. Ann Oncol 2005;16(suppl 8):viii7–12
ESMO Guideline Working Group. Epithelial ovarian carcinoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2007;18(suppl 2):ii12–14
Rao G, Crispens M, Rothenberg ML. Intraperitoneal chemotherapy for ovarian cancer: overview and perspective. J Clin Oncol 2007;25:2867–2872
Rose PG, Nerenstone S, Brady MF et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med 2004;351:2489–2497
Réf.
Gershenson DM. Management of ovarian germ cell tumors. J Clin Oncol 2007;25:2938–2943
Lai CH, Chang TC, Hsueh S et al. Outcome and prognostic factors in ovarian germ cell malignancies. Gynecol Oncol 2005;96:784–791
Lu KH, Gershenson DM. Update on the management of ovarian germ cell tumors. J Reprod Med 2005;50:417–425
Schmoll HJ, Souchon R, Krege S et al. European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol 2004;15:1377–1399
Zanetta G, Bonazzi C, Cantu M et al. Survival and reproductive function after treatment of malignant germ cell ovarian tumors. J Clin Oncol 2001;19:1015–1020
Réf.
Colombo N, Parma G, Zanagnolo V et al. Management of ovarian stromal tumors. J Clin Oncol 2007;25:2944–2951
Schumer ST, Cannistra SA. Granulosa cell tumor of the ovary. J Clin Oncol 2003;21:1180–1189
Uygun K, Aydiner A, Saip P et al. Clinical parameters and treatment results in recurrent granulosa cell tumor of the ovary. Gynecol Oncol 2003;88:400–403
Réf.
Gheorghisan-Galateanu A, Fica S, Terzea DC et al. Sertoli-Leydig cell tumor: a rare androgen-secreting ovarian tumor in postmenopausal women. J Cell Mol Med 2003;7:461–471
Schneider DT, Calaminus G, Wessalowksi R et al. Ovarian sex cord-stromal tumors in children and adolescents. J Clin Oncol 2003;12:2357–2363
Young RH, Scully RE. Ovarian Sertoli-Leydig cell tumors. A clinicopathological analysis of 207 cases. Am J SurgPathol 1985;8:543–569
Réf.
Altieri A, Franceschi S, Ferlay J et al. Epidemiology and aetiology of gestational trophoblastic diseases. Lancet Oncol 2003;4:670–678
Carney ME. Treatment of low risk gestational trophoblastic disease. Clin Obstet Gynecol 2003;46:579–592
Dainty LA, Winter WE, Maxwell GL. The clinical behavior of placental site trophoblastic tumor and contemporary methods of management. Clin Obstet Gynecol 2003;46:607–611
Ngan HY, Bender H, Benedet JL et al. Gestational trophoblastic neoplasia, FIGO 2000 staging and classification. Int J Gynaecol Obstet 2003;83(suppl 1):175–177
Smith HO, Kohorn E, Cole LA. Choriocarcinoma and gestational trophoblastic disease. Obstet Gynecol Clin North Am 2005;32:661–684
Soper JT, Mutch DG, Schink JC et al. Diagnosis and treatment of gestational trophoblastic disease: ACOG Practice Bulletin No. 53. Gynecol Oncol 2004;93:575–585
Wright JD, Mutch DG. Treatment of high-risk gestational trophoblastic tumors. Clin Obstet Gynecol 2003;46:593–606
Réf.
Bosch FX, Castellsagué X, De Sanjosé. HPV and cervical cancer: screening or vaccination? Br J Cancer 2008;98:15–21
Joura EA, Leodolter S, Hernandez-Avila M et al. Efficacy of a quadrivalent prohylactic human papillomavirus (types 6,11,16 and 18) L1virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 2007;369:2161–2170
Long HC. Management of metastatic cervical cancer. J Clin Oncol 2007;25:2966–2974
Mayrand MH, Duarte-Franco E, Rodrigues I et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 2007;1579–1588
Monk BJ, Tewari KS, Koh WJ. Multimodality therapy for locally advanced cervical carcinoma. J Clin Oncol 2007;25:2952–2965
Saslow D, Castle PE, Cox JT et al. ASCO Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin 2007;57:7–28
Schiffman M, Castle PE, Jeronimo J et al. Human papillomavirus and cervical cancer. Lancet 2007;370:890–907
Stanley M. Prophylactic HPV vaccines: prospects for eliminating ano-geTINal cancer. Br J Cancer 2007;96:1320–1323
Woodman CBJ, Collins SI, Young LS. The natural history of cervical HPV infection: unresolved issues. Nat Rev Cancer 2007;7:11–22
Réf.
Amant F, Moermann P, Timmermann D et al. Endometrial cancer. Lancet 2005;366:491–505
Carey MS, Gawlik C, Fung-Kee-Fung M et al. Systematic review of systemic therapy for advanced or recurrent endometrial cancer. Gynecol Oncol 2006;101:158–167
Fleming GF. Systemic chimiothérapie for uterine carcinoma: metastatic and adjuvant. J Clin Oncol 2007;25:2983–2990
Hecht JL, Mutter Gl. Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol 2006;24:4783–4791
Humber CE, Tierney JF, Symonds RP et al. Chimiothérapie for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration. Ann Oncol 2007;18:409–420
Markman M. Hormonal therapy of endometrial cancer. Eur J Cancer 2005;41:673–675
Million Women Study Collaborators. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 2005;365:1543–1551
Polyzos NP, Pavlidis N, Paraskevaidis E et al. Randomized evidence on chimiothérapie and hormonal therapy regimens for advanced endometrial cancer. Eur J Cancer 2006;42:319–326
Réf.
Curtin JP, Blessing JA, Soper JT et al. Paclitaxel in the treatment of carcinosarcoma of the uterus: a gynecologic oncology group study. Gynecol Oncol 2001;83:268–270
Kempson RL, Hendrickson MR. Smooth muscle, endometrial stromal, and mixed Mullerian tumors of the uterus. Mod Pathol 2000;13:328–342
Nordal RN, Kjorstad KE, Stenwig AE et al. Leiomyosarcoma (LMS) and endometrial stromal sarcoma (ESS) of the uterus. Int J Gynecol Cancer 1993;3:110–115
Sutton GP, Brunetto VL, Kilgore L et al. A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus. Gynecol Oncol 2000;79:147–153
Toyoshima M, Akahira J, Matsunaga G et al. Clinical experience with combination paclitaxel and carboplatin therapy for advanced or recurrent carcinosarcoma of the uterus. Gynecol Oncol 2004;94:774–778
Van Rijswijk REN, Vermorken JB, Reed N et al. Cisplatin, doxorubicin and ifosfamide in carcinosarcoma of the female geTINal tract. Eur J Cancer 2003;39:481–487
Yamada SD, Burger RA, Brewster WR et al. Pathologic variables and adjuvant therapy as predictors of recurrence and survival for patients with surgically evaluated carcinosarcoma of the uterus. Cancer 2000;88:2782–2786
Réf.
Creasman WT. Vaginal cancers. Curr Opin Obstet Gynecol. 2005:17:71–76
Grigsby PW. Vaginal cancer. Curr Treat Options Oncol 2002;3:125–130
Réf.
Coleman RL, Santoso JT. Vulvar carcinoma. Curr Treat Options Oncol 2000;1:177–190
Fonseca-Moutinho JA. Recurrent vulvar cancer. Clin Obstet Gynecol 2005;48:879–883
Geisler JP, Manahan KJ, Buller RE. Neoadjuvant chimiothérapie in vulvar cancer: avoiding primary exenteration. Gynecol Oncol 2006;100:53–57
Hakim AA, Terada KY. Sentinel node dissection in vulvar cancer. Curr Treat Options Oncol 2006;7:85–91
Montana GS. Carcinoma of the vulva: combined modality treatment. Curr Treat Options Oncol 2004;5:85–95
Rouzier R, Haddad B, Atallah D et al. Surgery for vulvar cancer. Clin Obstet Gynecol 2005;48:869–878
Tyring SK. Vulvar squamous cell carcinoma: guidelines for early diagnosis and treatment. Am J Obstet Gynecol 2003;189(3 suppl):S17–23
Van Seters M, Van Beurden M, Ten Kate FBW et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. N Engl J Med 2008;358:1465–1473
Réf.
Albers P, Albrecht W, Algaba F et al. Guidelines on testicular cancer. Eur Urol 2005;48:885–894
Dearnaley D, Huddart R, Horwich A. Managing testicular cancer. BMJ 2001;322:1583–1588
De Wit R, Fizazi K. Controversies in the management of clinical stages I testis cancer. J Clin Oncol 2006;24:5482–5492
ESMO Guidelines Working Group. Testicular seminoma: ESMO Clinical Recommendation for diagnosis, treatment and follow-up. Ann Oncol 2007;18(suppl 2):ii40–41
ESMO Guidelines Working Group. Mixed or non-seminomatous germ-cell tumors: ESMO Clinical Recommendation for diagnosis, treatment and follow-up. Ann Oncol 2007;18(suppl 2):ii42–43
Horwich A, Shipley J, Huddart R. Testicular germ-cell cancer. Lancet 2006;367:754–765
MacVicar GR, Pienta KJ. Testicular cancer. Curr Opin Oncol 2004;16:253–256
Schmoll HJ, Souchon R, Krege S et al. European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG).Ann Oncol 2004;15:1377–1399
Van Dijk MR, Steyerberg EW, Habbema JDF. Survival of non-seminomatous germ cell cancer patients according to the IGCC classification: An update based on meta-analysis. Eur J Cancer 2006;42:820–826
Réf.
Bokemeyer C, Nichols CR, Droz JP et al. Extragonadal germ cell tumors of the mediastinum and retroperitoneum: results from an international analysis. J Clin Oncol 2002;20:1864–1873
De Giorgi U, Demirer T, Wandt H et al. Second-line high-dose chimiothérapie in patients with mediastinal and retroperitoneal primary non-seminomatous germ cell tumors. Ann Oncol 2005; 16:146–151
Göbel U, Schneider DT, Calaminus G et al. Germ-cell tumors in childhood and adolescence. Ann Oncol 2000;11:263–271
Hartmann JT, Nichols CR, Droz JP et al. Prognostic variables for response and outcome in patients with extragonadal germ-cell tumors. Ann Oncol 2002;13:1017–1028
Schmoll HJ, Souchon R, Krege S et al. European consensus on the diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol 2004;15:1377–1399
Réf.
Antonarakis ES, Blackford AL, Garrett-Mayer E et al. Survival in men with nonmetastatic prostate cancer treated with hormone therapy. J Clin Oncol 2007;25:4998–5008
Basch EM, Somerfield MR, Beer TM et al. ASCO Endorsement of the Cancer Care Ontario Practice Guideline on nonhormonal therapy for men with metastatic hormone-refactory (castration-resistant) prostate cancer. J Clin Oncol 2007;25:5313–5318
ESMO Guidelines Working Group. Prostate cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2007;18(suppl 2):ii36–37
Lilja H, Ulmert D, Vickers AJ. Prostate-specific antigen and prostate cancer: prediction, detection and moTINoring. Nat Rev Cancer 2008;8:268–278
Loblaw DA, Virgo KS, Nam R et al. ITINial hormonal management of androgen-sensitive metastatic, recurrent or progressive prostate cancer: 2006 Update of an ASCO Practice Guideline. J Clin Oncol 2007;25:1596–1605
Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med 2003;349:366–381
Speight JL, Roach M. Radiothérapie in the management of clinically localized prostate cancer: evolving standards, consensus, controversies and new directions. J Clin Oncol 2005;23:8176–8185
Taichman RS, Loberg RD, Mehra R et al. The evolving biology and treatment of prostate cancer. J Clin Invest 2007;117:2351–2361
Walsh PC, DeWeese Tl, Eisenberger MA. Localized Prostate Cancer. N Engl J Med 2007;357:2696–2705
Réf.
Castellsague X, Bosch FX, Munoz N et al. Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners. N Engl J Med 2002;346:1105–1112
Culkin DJ, Beer TM. Advanced penile carcinoma. J Urol 2003;170(2 Pt 1):359–365
McDougal WS. Advances in the treatment of carcinoma of the penis. Urology 2005;66(suppl 5):114–117
Misra S, Chaturvedi A, Misra NC. Penile carcinoma: a challenge for the developing world. Lancet Oncol 2004;5:240–247
Mosconi AM, Roila F, Gatta G et al. Cancer of the penis. Crit Rev Oncol Hematol 2005;53:165–177
Rippentrop JM, Joslyn SA, Konety BR. Squamous cell carcinoma of the penis: evaluation of data from the surveillance, epidemiology, and end results program. Cancer 2004;101:1357–1363
Sanchez-Ortiz RF, Pettaway CA. The role of lymphadenectomy in penile cancer. Urol Oncol 2004;22:236–244
Solsona E, Algaba F, Horenblas S et al. European Association of Urology Guidelines on Penile Cancer. Eur Urol 2004;46:1–8
Réf.
Costa LJ, Drabkin HA, Renal cell carcinoma: new developments in molecular biology and potential for targeted therapies. Oncologist 2007;12:1404–1415
Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med 2005;353:2477–2490
Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125–134
Garcia JA, Rini Bl. Recent progress in the management of advanced renal cell carcinoma. CA Cancer J Clin 2007;57:112–125
Hudes G, Carducci M, Tomczak P et al. Temsirolismus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271–2281
Lam JS, Breda A, Belldegrun AS et al. Evolving principles of surgical management and prognostic factors for outcome in renal cell carcinoma. J Clin Oncol 2006;24:5565–5575
Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115–124
Pavlovich CP, Schmidt LS. Searching for the hereditary causes of renal cell carcinoma. Nat Rev Cancer 2004:4:381–393
Yang JC, Childs R. Immunotherapy for renal cell cancer. J Clin Oncol 2006;24:5576–5583
Réf.
Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Adjuvant chimiothérapie for invasive bladder cancer. Cochrane Database Syst Rev. 2006;(2):CD006018
Amiel GE, Lerner SP. Combining surgery and chimiothérapie for invasive bladder cancer. Expert Rev Anticancer Ther 2006;6:281–291
Bamias A, Tiliakos I, Karali MD et al. Systemic chimiothérapie in inoperable or metastatic bladder cancer. Ann Oncol 2006;17:553–561
Borden LS Jr, Clark PE, Hall MC. Bladder cancer. Curr Opin Oncol 2005;17:275–280
ESMO Guidelines Working Group. Invasive bladder cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2007;18(suppl 2):ii38–39
Garcia JA, Dreicer R. Systemic chimiothérapie for advanced bladder cancer: update and controversies. J Clin Oncol 2006;24:5545–5551
Habuchi T, Marberger M, Droller MJ et al. Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers. Urology 2005;66(6 suppl 1):64–74
Rödel C, Weiss C, Sauer R. Trimodality treatment and selective organ preservation for bladder cancer. J Clin Oncol 2006;24:5536–5544
Wolff EM, Liang G, Jones PA. Mechanisms of disease: genetic and epigenetic alterations that drive bladder cancer. Nat Clin Pract Urol 2005;2:502–510
Réf.
Baudin E, Schlumberger M. New therapeutic approaches for metastatic thyroid carcinoma. Lancet Oncol 2007;8:148–156
Fernandes JK, Jour TA, Richardson MS et al. Overview of the management of differentiated thyroid cancer. Curr Treat Options Oncol 2005;6:47–57
Kebebew E, Greenspan FS, Clark OH et al. Anaplastic thyroid carcinoma. Cancer 2005;103:1330–1335
Kondo T, Ezzat S, Asa SL. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 2006;6:292–306
Patel KN, Shaha AR. Poorly differentiated and anaplastic thyroid cancer. Cancer Control. 2006; 13:119–128
Sherman SI. Thyroid carcinoma. Lancet 2003;361:501–511
Traugott A, Moley JF. Medullary thyroid cancer: medical management and follow-up. Curr Treat Options Oncol 2005;6:339–346
Réf.
Durá I, Salazar R, Casanovas O et al. New drug development in digestive neuroendocrine tumors. Ann Oncol 2007;18:1307–1313
Kulke M. Advances in the treatment of neuroendocrine tumors. Curr Treat Options Oncol 2005;6:397–409
Lal A, Chen H. Treatment of advanced carcinoid tumors. Curr Opin Oncol 2006; 18:9–15
Oberg K, Kvols L, Caplin M et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 2004;15:966–973
Ramage JK, Davies AH, Ardill J et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut 2005;54(suppl 4):iv1–16
Soga J. Early-stage carcinoids of the gastrointestinal tract. Cancer 2005;103:1587–1595
Zuetenhorst JM, Taal BG. Metastatic carcinoid tumors. Oncologist 2005;10:123–131
Réf.
Kim WY, Kaelin WG. Role of VHL mutation in human cancer. J Clin Oncol 2004;24:4991–5004
Lenders JWM, Eisenhofer G, Mannelli M et al. Phaeochromocytoma. Lancet 2005;366:665–675
Lonser RR, Glenn GM, Walther M et al. Von Hippel-Lindau disease. Lancet 2003;361:2059–2067
Marx SJ. Molecular genetics of multiple endocrine neoplasia types 1 and 2. Nat Rev Cancer 2005;5:367–375
Neumann HPH, Bausch B, McWhinney SR et al. Germline mutations in nonsyndromic pheochromocytoma. N Engl J Med 2002;346:1459–1466
Schiavi F, Boedecker cc, Bausch B et al. Predictors and prevalence of paraganglioma syndrome associated with mutations of the SDHC gene. JAMA 5005;294:2057–2063
Scholz T, Eisenhofer G, Pacak K et al. Current treatment of malignant pheochromocytoma. J Clin Endocrinol Metab 2007;92:121–125
Réf.
Cobb WS, Kercher KW, Sing RF et al. Laparoscopic adrenalectomy for malignancy. Am J Surg 2005;189:405–411
Kirschner LS. Emerging treatment strategies for adrenocortical carcinoma. J Clin Endocrinol Metab 2006;91:14–21
Libe R, Bertherat J. Molecular genetics of adrenocortical tumours, from familial to sporadic diseases. Eur J Endocrinol 2005;153:477–487
Shen WT, Sturgeon C, Duh OY. From incidentaloma to adrenocortical carcinoma: the surgical management of adrenal tumors. J Surg Oncol 2005;89:186–192
Sidhu S, Sywak M, Robinson B et al. Adrenocortical cancer. Curr Opin Oncol 2004;16:13–18
Young WE. The incidentally discovered adrenal mass. N Engl J Med 2007;356:601–610
Réf.
Bradshaw C, Kakar SS: Pituitary tumor transforming gene: an important gene in normal cellular functions and tumorigenesis. Histol Histopathol. 2007; 22:219–226.
Melmed S, Acromegaly. N Engl J Med 2006; 355:2558–2573.
Minematsu T, Miyai S, Kajiya H, et al. Recent progress in studies of pituitary tumor pathogenesis. Endocrine 2005;28:37–41.
Kaltsas GA, Grossmann AB: Malignant pituitary tumors. Pituitary 1998(1): 69–81.
Simard MF: Pituitary tumor endocrinopathies and their endocrine evaluation. Neurosurg Clin N Am. 2003; 14:41–54.
Réf.
Curtin JA, Fridlyand J, Kageshita T et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005;353:2135–2147
ESMO Guidelines Working Group. Cutaneous malignant melanoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2007;18(suppl 2):ii71–73
Fears TR, Guerry DP, Pfeiffer RM et al. Identifying individuals at high risk of melanoma: a practical predictor of absolute risk. J Clin Oncol 2006;24:3590–3596
Ives NJ, Stowe RL, Lorigan P et al. Chimiothérapie compared with biochimiothérapie for treatment of meta-static melanoma. J Clin Oncol 2007;25:5426–5434
Miller AJ, Mihm MC. Melanoma. N Engl J Med 2006;355:51–65
Morton DL, Thompson JF, Chochran AJ et al. Sentinel-node biopsy or nodal observation in melanoma. N Englj Med 2006;355:1307–1317
Scoggins CR, Chagpar AB, Martin RC et al. Should sentinel lymph-node biopsy be used routinely for staging melanoma and breast cancers? Nat Clin Pract Oncol 2005;2:448–455
Thompson JF, Scolyer RA, Kefford RF. Cutaneous melanoma. Lancet 2005;365:687–701
Verma S, Quirt I, McCready D et al. Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma. Cancer 2006; 106:1431–1442
Réf.
Bath FJ, Bong J, Perkins W et al. Interventions for basal cell carcinoma of the skin. Cochrane Database Syst Rev2003;2:CD003412
Brooke RC. Basal cell carcinoma. Clin Med 2005;5:551–554
Rubin AI. Basal cell carcinoma. N Engl J Med 2005;353:2262–2269
Réf.
Albert MR, Weinstock MA. Keratinocyte carcinoma. CA Cancer J Clin 2003;53:292–302
Boukamp P. Non-melanoma skin cancer: what drives tumor development and progression? Carcinogenesis 2005;26:1657–1667
Lane JE, Kent DE. Surgical margins in the treatment of nonmelanoma skin cancer and Mohs micrographic surgery. Curr Surg 2005;62:518–526
Rinker MH, Fenske NA, Scalf LA et al. Histologic variants of squamous cell carcinoma of the skin. Cancer Control 2001;8:354–363
Réf.
Goessling W, McKee PH, Mayer RJ. Merkel cell carcinoma. J Clin Oncol 2002;20:588–598
McAfee WJ, Morris GG, Mendenhall CM et al. Merkel cell carcinoma: treatment and outcomes. Cancer 2005;104:1761–1764
Pectasides D, Pectasides M, Economopoulos T. Merkel cell cancer of the skin. Ann Oncol 2006;17:1489–1495
Poulsen M. Merkel-cell carcinoma of the skin. Lancet Oncol 2004;5:593–599
Réf.
Clark MA, Fisher C, Judson I et al. Soft-tissue sarcomas in adults. N Engl J Med 2005;353:701–711
Cormier JN, Pollock RE. Soft tissue sarcomas. CA Cancer J Clin 2004;54:94–109
ESMO Guidelines Working Group. Soft tissue sarcomas: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2007;18(Suppl.2):ii74–76
Kotilingam D, Lev DC, Lazar AJF et al. Staging soft tissue sarcoma: evolution and change. CA Cancer J Clin2006;56:282–291
Mocellin S, Rossi CR, Brandes A et al. Adult soft tissue sarcomas: conventional therapies and molecularly targeted approaches. Cancer Treat Rev 2006;32:9–27
Réf.
Blay JY, Bonvalot S, Casali P et al. Consensus meeting for the management of gastrointestinal stromal tumors (GISTs). Ann Oncol 2005;16:566–578
Chen LL, Sabripour M, Andtbacka RH et al. Imatinib resistance in gastrointestinal stromal tumors. Curr Oncol Rep 2005;7:293–299
Demetri G, Von Mehren M, Blanke CD et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472–480
ESMO Guidelines Working Group. Gastrointestinal stromal tumors: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2007;18(Suppl.2):ii27–29
Kosmadakis N, Visvardis EE, Kartsaklis P et al. The role of surgery in the management of GISTs in the era of imatinib mesylate effectiveness. Surg Oncol 2005;14:75–84
Rubin BP, Heinrich MC, Corless CL. Gastrointestinal stromal tumor. Lancet 2007;369:1731–1741
Van der Zwan SM, De Matteo RP. Gastrointestinal stromal tumor. Cancer 2005;104:1781–1788
Réf.
Bernstein M, Kovar H, Paulussen M et al. Ewing’s sarcoma family of tumors: current management. Oncologist 2006; 11503–11519
Ek ET, Choong PF. The role of high-dose therapy and autologous stem cell transplantation for pediatric bone and soft tissue sarcomas. Expert Rev Anticancer Ther 2006;6:225–237
ESMO Guidelines Working Group. Ewing’s sarcoma of bone: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2007;18(Suppl.2):ii79–80
Janknecht R. EWS-ETS oncoproteins: the linchpins of Ewing tumors. Gene 2005;363:1–14
Kennedy JG, Frelinghuysen P, Hoang BH. Ewing sarcoma: current concepts in diagnosis and treatment. Curr Opin Pediatr 2003;15:53–57
Thacker MM, Temple HT, Scully SP. Current treatment for Ewing’s sarcoma. Expert Rev Anticancer Ther 2005;5:319–331
Réf.
ESMO Guidelines Working Group. Osteosarcoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2007;18(Suppl.2):ii77–78
Ferguson WS, Goorin AM. Current treatment of osteosarcoma. Cancer Invest 2001;19:292–315
Grimer RJ. Surgical options for children with osteosarcoma. Lancet Oncol 2005;6:85–92
Heck RK, Peabody TD, Simon MA. Staging of primary malignancies of bone. CA Cancer J Clin 2006;56:366–375
Marina N, Gebhardt M, Teot L et al. Biology and therapeutic advances for pediatric osteosarcoma. Oncologist 2004;9:422–441
Miller SL, Hoffer FA. Malignant and benign bone tumors. Radiol Clin North Am 2001;39:673–699
Ngarajan R, Clohisy D, Weigel B. New paradigms for therapy of osteosarcoma. Curr Oncol Rep 2005;7:410–414
Wang LL. Biology of osteogenic sarcoma. Cancer J 2005;11:294–305
Wittig JC, Bickels J, Priebat D et al. Osteosarcoma: a multidisciplinary approach to diagnosis and treatment. Am Fam Physician 2002;65:1123–1132
Réf.
Behin A, Hoang-Xuan K, Carpentier AF et al. Primary brain tumors in adults. Lancet 2003;361:323–331
ESMO Guidelines Working Group. Malignant glioma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2007;18(Suppl.2):ii69–70
Grier JT, Batchelor T. Low-grade gliomas in adults. Oncologist 2006;11:681–693
Jaeckle KA, Ballmann KV, Rao RD et al. Current strategies in treatment of oligodendroglioma: evolution of molecular signatures of response. J Clin Oncol 2006;24:1246–1252
Lang FF, Gilbert MR. Diffusely infiltrative low-grade gliomas in adults. J Clin Oncol 2006;24:1236–1245
Maris JM, Hogarty MD, Bagatell R et al. Neuroblastoma. Lancet 2007;369:2106–2120
Reardon DA, Rich JN, Friedman HS et al. Recent advances in the treatment of malignant astrocytoma. J Clin Oncol 2006;24:1253–1265
Stupp R, Hegi ME, Gilbert MR et al. Chemoradiothérapie in malignant glioma: standard of care and future directions. J Clin Oncol 2007;25:4127–4136
Van den Bent MJ, Hegi ME, Stupp R. Recent developments in the use of chimiothérapie in brain tumors. Eur J Cancer 2006;42:582–588
Réf.
Chorost MI, Lee MC, Yeoh CB et al. Unknown primary. J Surg Oncol 2004;87:191–203
ESMO Guidelines Working Group. Cancer of unknown primary site: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2007;18(Suppl.2):ii81–82
Hillen HE Unknown primary tumours. Postgrad Med J 2000;76:690–693
Pavlidis N, Fizazi K. Cancer of unknown primary (CUP). Crit Rev Oncol Hematol 2005;54:243–250
Van de Wouw AJ, Jansen RLH, Speel EJM et al. The unknown biology of the unknown primary tumour. Ann Oncol 2003;14:191–196
Varadhachary GR, Abbruzzese JL, Lenzi R. Diagnostic strategies for unknown primary cancer. Cancer 2004;100:1776–1785
Réf.
Bogenrieder T, Herlyn M. Axis of evil. Molecular mechanisms of cancer metastasis. Oncogene 2003;22:6524–6536
Cao Y. Emerging mechanisms of tumor lymphangiogenesis and lymphatic metastasis. Nat Rev Cancer 2005;5:735–742
Eccles SA, Welch DR. Metastasis: recent discoveries and novel treatment strategies. Lancet 2007;369:1742–1757
Entschladen F, Drell TL, Lang K et al. Tumor-cell migration, invasion and metastasis: navigation by neuro-transmitters. Lancet Oncol 2004;5:254–258
Hunter K. Host genetics influence tumour metastasis. Nat Rev Cancer 2006;6:141–146
Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature 2001;411:375–379
Pantel K, Brakenhoff RH. Dissecting the metastatic cascade. Nat Rev Cancer 2004;4:448–456
Steeg PS. Tumor metastasis: mechanistics insights and clinical challanges. Nature Med 2006;12:895–904
Weigelt B, Peterse JL, Van’t Veer LJ. Breast cancer metastasis: markers and models. Nat Rev Cancer 2005;5:591–602
Réf.
Eichler AF, Loeffler JS. Multidisciplinary management of brain metastases. Oncologist 2007;12:884–898
Kaap EC, Niel CG, Vecht CJ. Therapeutic management of brain metastasis. Lancet Neurol 2005;4:289–298
Khuntia D, Brown P, Li J et al. Whole-brain radiothérapie in the management of brain mestastasis. J Clin Oncol 2006;24:1295–1304
Klimo P, Schmidt MH. Surgical management of spinal metastases. Oncologist 2004;9:188–196
Langer CL, Mehta MP. Current management of brain metastases, with a focus on systemic options. J Clin Oncol 2005;23:6207–6219
Van den Bent MJ. The role of chimiothérapie in brain metastases. Eur J Cancer 2003;39:2114–2120
Vogelbaum MA, Suh JH. Resectable brain metastases. J Clin Oncol 2006;24:1289–1294
Réf.
Balm M, Hammack J. Leptomeningeal carcinomatosis: presenting features and Facteurs pronostiques. Arch Neurol 1996;53:626–632
Chamberlain MC. Combined-modality treatment of leptomeningeal gliomatosis. Neurosurgery 2003;52:324
Kesari S, Batchelor TT. Leptomeningeal metastases. Neurol Clin 2003;21:25–66
Omuro AM, Lallana EC, Bilsky MH, DeAngelis LM. Ventriculoperitoneal shunt in patients with leptomeningeal metastasis. Neurology 2005;64:1625–1627
Réf.
Briccoli A, Rocca M, Salone M et al. Resection of recurrent pulmonary metastases in patients with osteosarcoma. Cancer 2005;104:1721–1725
Kondo H, Okumura T, Ohde Y et al. Surgical treatment for metastatic malignancies. Pulmonary metastasis: indications and outcome. Int J Clin Oncol 2005;10:81–85
Schreiber G, Pitterle D, Kim YC et al. Molecular genetic analysis of primary lung cancer and cancer metastatic to the lung. Anticancer Res 1999;19:1109–1115
Thao B, Schwartz LH, Moskowitz CS et al. Pulmonary metastases: effect of CT section thickness on measurement: initial experience. Radiology 2005;234:934–939
Van Putte BP, Hendriks JM, Romijn S et al. Isolated lung perfusion for the treatment of pulmonary metastases. Surg Oncol 2003;12:187–193
Yoneda KY, Louie S, Shelton DK. Approach to pulmonary métastases. Curr Opin Pulm Med 2000;6:356–363
Réf.
Khatri VP, Petrelli NJ, Belghiti J. Extending the frontiers of surgical therapy for hepatic colorectal metastases: is there a limit? J Clin Oncol 2005;23:8490–8499
Malafosse R, Penna C, Sa Cunha A et al. Surgical management of hepatic metastases from colorectal malignancies. Ann Oncol 2001;12:887–894
Mocellin S, Pilati P, Lise M et al. Meta-analysis of hepatic arterial infusion for unresectable liver metastases from colorectal cancer: the end of an era? J Clin Oncol 2007;25:5649–5654
Pawlik TM, Schulick RD, Choti MA. Expanding criteria for resectability of colorectal liver metastases. Oncologist 2008;13:51–64
Venook AP, Warren RS. Therapeutic approaches to metastasis confined to the liver. Curr Oncol Rep 2001;3:109–115
Réf.
Coleman RE. Management of bone metastases. Oncologist 2000;5:463–470
Mercadante S, Fulfaro R Management of painful bone metastases. Curr Opin Oncol 2007;19:308–314
Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004;350:1655–1664
Serafini AN. Therapy of metastatic bone pain. J Nucl Med 2001;42:895–906
Van Poznack C, Nadal C. Bone integrity and bone metastases in breast cancer. Curr Oncol Rep 2006;8:22–28
Réf.
Abu-Shakra M, Buskila D, Ehrenfeld M et al. Cancer and autoimmunity: autoimmune and rheumatic features in patients with malignancies. Ann Rheum Dis 2001;60:433–441
Bollanti L, Riondino G, Strollo E Endocrine paraneoplastic syndromes with special reference to the elderly. Endocrine 2001;14:151–157
Darnell RB, Posner JB. Paraneoplastic syndromes involving the nervous system. N Engl J Med 2003;349:1543–1554
De Beukelaar JW, Smitt PAS. Managing paraneoplastic neurological disorders. Oncologist 2006;11:292–305
Stone SP, Buescher LS. Life-threatening paraneoplastic neurological disorders. Oncologist 2006;23:301–306
Rights and permissions
Copyright information
© 2011 Springer-Verlag France, Paris
About this chapter
Cite this chapter
Daskalakis, M. et al. (2011). Tumeurs solides. In: Précis d’hématologie et d’oncologie. Springer, Paris. https://doi.org/10.1007/978-2-287-99342-8_8
Download citation
DOI: https://doi.org/10.1007/978-2-287-99342-8_8
Publisher Name: Springer, Paris
Print ISBN: 978-2-287-99341-1
Online ISBN: 978-2-287-99342-8